Cytek Biosciences, Inc. (CTKB) Earnings Call Transcript
February 26, 2026
Earnings Call Speaker Segments
Thanks, operator. Cytek Biosciences put out its financial results earlier today, covering both the fourth quarter and the full year that closed on December 31, 2025. Should you not have gotten that news release, or if you want your name added to the company's distribution list, just email investors@cytekbio.com. You can also find a copy of the release in the investor relations area of Cytek's site, investors.cytekbio.com. With me on today's call from Cytek are Wenbin Jiang, our CEO, and Bill McCombe, our CFO. Just so you know, throughout today's call we'll be walking through a slide presentation, and that deck has been posted in the investor section of our corporate website. As a reminder, on Slide two, some of what we say today will be forward-looking statements under the federal securities laws, and that includes remarks about Cytek's business plans, strategies, opportunities, and financial projections. Such statements rest on what the company currently expects, and they come with substantial risks and uncertainties by their very nature, which might cause actual results or events to differ materially from what those statements anticipate. You can find more detail on these risks and uncertainties in our slide presentation, under the section titled "Forward-Looking Statements," in the press release Cytek issued today, and in Cytek's filings with the SEC. Today's call will also touch on certain financial measures that aren't calculated under generally accepted accounting principles. For more information about our use of non-GAAP financial measures, including reconciliations to the most directly comparable GAAP financial measures, please see our slide presentation and today's press release. Although the company believes these non-GAAP financial measures give investors useful information, presenting this information isn't meant to be viewed on its own or as a replacement for the financial information presented under GAAP. Unless the law requires it, Cytek disclaims any duty to update any forward-looking statements, whether due to new information, future events, or shifts in its expectations. This conference call includes time-sensitive information and is accurate only as of the live broadcast on February 26, 2026; with that, I'll hand the call over to Wenbin.
Thank you, Paul. Hello, everyone, and we appreciate your interest in Cytek. During this call, I'd like to begin by discussing how we performed in the fourth quarter and for the full year 2025, and then I'll hand things over to Bill, who will walk through our financials and outlook in detail. If you'll turn to Slide three; we finished 2025 in line with what we expected, and we delivered revenue growth that accelerated quarter-over-quarter across the year, even with difficult industry conditions. Revenue for the fourth quarter of 2025 came in at $62.1 million, which is an 8% increase year-over-year versus the same period in 2024, and notably, that's the highest quarterly revenue Cytek has ever achieved. So, what drove this increase was really just more of what we saw in Q3 — things settling down and picking up in the U.S., a rebound across the E.U., continuing momentum in APAC, and healthy growth in our recurring revenue lines globally. Moving on to Slide four. If you break it down by region, Q4 saw EMEA and APAC each post year-over-year revenue percentage gains in the double digits, with good increases across instruments, reagents, and service. Within EMEA, the year-over-year revenue improvement in Q4 came largely from robust instrument demand among academic and government customers, together with ongoing strength in service revenue — partly offset by lower instrument revenue from biotech, pharma, and CRO customers. In the U.S. During Q4 of 2025, our total revenue grew at a mid-single digit rate compared with the same period a year earlier, and the momentum came from a change in sentiment across the academic and government market. Partly countering that gain was lower instrument sales into the biotech, pharma, and CRO market — a pattern of usual ups and downs for this sector, especially following a robust third quarter. Let's turn to Slide five. Revenue for the entire 2025 year reached $201.5 million, up 1% from 2024. I'd like to briefly note how our top-line growth strengthened over the course of 2025. In the first six months, total revenue was down nearly 5% versus the prior year, a result of public policy matters that weighed on life sciences spending. Things turned around for us in the back half of the year — total revenue came in 5% higher than what we saw during the same period in 2024. Getting back to growth like this speaks to better market conditions and stronger demand from customers. What matters even more is that our 2025 results as a whole show how resilient this business is, especially when you set them against signs of shrinking demand for cell analysis and life science instruments that persisted through the close of Q3. We credit our ability to grow revenue in 2025 to a few things: a powerful brand and technology base, revenue spread across many different geographies, and an expanding slice of that revenue coming from recurring sources. And we expect that growth trajectory to carry forward into 2026. I'd like to take a moment now to walk you through where our team stands on the strategic pillars at the heart of what we do — instrument, application, bioinformatics, and clinical — all of which continue to strengthen Cytek's standing as a leader in next-gen cell analysis solutions. Turning to Slide six, we'll cover our flagship instrument. We placed 208 instruments around the globe during Q4, bringing Cytek's installed base to 3,664 units in total. Considering the difficult conditions the market presented in 2025, the revenue growth we saw from our FFPE instruments, in our view, demonstrates the strength of Cytek's product performance, the recognition our brand enjoys, and the enduring health of our core business. One thing we're particularly pleased by is the increase in unit volume for sales orders — that figure climbed 22% across 2025 compared with the prior year, and the pace picked up further in Q4, reaching 26% growth over the equivalent quarter in the previous year. Our new Cytek Aurora Evo system has also performed very well in our eyes. It hit the market last May, and in that short stretch it has found impressive traction, driving a 21% lift in units for the Aurora category overall in Q4 versus Q4 of 2024. On top of that, I'm happy to share that the Muse Micro system was just named the 2025 BioTech Breakthrough Awards winner for Drug Discovery Solution of the Year. As we mentioned before, the Muse Micro analyzer is a perfect fit for researchers and labs looking for affordable flow cytometry options, and it's been received very well since debuting last year. These fresh product launches demonstrate our dedication to staying at the leading edge of technology innovation in cell analysis broadly, and flow cytometry in particular. Now I'd like to discuss our next growth pillar, applications, which consists of our reagent business; we achieved over 20% growth in reagents during the fourth quarter across every geographic region we serve except the U.S. Our reagent growth keeps being fueled by the enhancements we made in 2025, such as best-in-class delivery times, an extensive reagent catalog, and fresh initiatives and strategies for reagent sales. Now to Slide seven. Our recurring revenue keeps getting stronger as our installed instrument base grows; throughout 2025, recurring revenue made up 34% of total revenue, and notably rose 21% year-over-year. We anticipate that recurring revenue's share of total revenue will keep climbing steadily as cumulative instrument placements increase, and will represent a progressively bigger portion of our business as time goes on. On the bioinformatics side, our software ecosystem remains a potent growth engine. The sophisticated software built right into our instruments, paired with what the Cytek Cloud can do, is highly prized by our customers and is speeding up adoption of our products. By the end of 2025, users on the Cytek Cloud had increased to more than 24,000, which amounts to growth exceeding 50% within just one year, and works out to almost eight users per installed FFPE instrument. Our growing digital presence boosts the appeal of our offerings overall and helps push reagent revenue higher. Before I get to our financial results, I want to call attention to the significant operational strides we made in 2025. Near the start of the year, we opened a new manufacturing facility in Singapore and streamlined our wider global operational footprint. So these moves really bolstered how we manufacture regionally, and they made our supply chain even more resilient. What makes me especially proud is that the site in Singapore was bringing in revenue in under 100 days after we kicked off the build-out. And just as important, these efforts put us in a spot to soften the blow from tariff policies around the world that are still taking shape. At this point, I'd like to turn things over to Bill to walk through our financials.
Thank you, Wenbin. Prior to getting into the results for the quarter and the full year, I'd like to offer some thoughts on the macroeconomic patterns that unfolded over the four quarters of 2025. Starting with Q1, uncertainty around the macro backdrop and soft demand meant total revenue fell 8% compared with the same period a year earlier. During Q2 and Q3, top-line growth leveled out, coming in at -2% and +2%, as gains in our service business and in APAC were canceled out by declines, most notably in EMEA. Then in Q4, exactly as we had anticipated, EMEA returned to stability while the remaining markets kept expanding, pushing overall revenue growth up to 8%. Our view is that this reversal points to more lasting conditions in our markets, since we've watched these patterns carry forward into 2026 — and that is what shaped the full year 2026 guidance I'll walk you through shortly. Moving to Slide eight. Revenue for the fourth quarter came to $62.1 million, an 8% increase versus the prior-year period. The improvement came from robust results worldwide in service and reagents, sustained strength in instrument demand throughout Asia Pacific, and a recovery in EMEA instrument demand from academic and government customers. Foreign exchange also played a role, adding 3% to growth during the quarter. Within the U.S., instrument revenue held steady, as gains among academic and government customers balanced out weaker demand from biotech and pharma. On a global basis for the quarter, revenue from academic and government customers rose 33%, helped by an easy comparison to a weak prior year, whereas biopharma revenue fell 6% against a tough Q4 the year before. Product revenue — instruments plus reagents — rose 3% relative to Q4 of 2024, fueled by double-digit improvements in APAC and EMEA along with a low single-digit increase in the U.S. U.S. product revenue carried on the steady pattern seen in Q3, thanks to a strong double-digit rise in instrument revenue from academic and government customers against a soft fourth quarter in 2024. That gain was offset by softness in pharma biotech instrument sales during Q4, following heavy purchasing in the third quarter of 2025. Instrument sales in the U.S. got a lift from the introduction of our new Aurora Evo instrument, together with pent-up demand from academic and government customers and their stabilized funding. In EMEA, conditions looked much like those in the U.S. The double-digit percentage gain in EMEA product revenue stemmed mainly from unusually large increases in revenue from academic and government customers relative to a weak Q4 in 2024. And as in the U.S., EMEA revenue from pharma biotech was soft in Q4 versus a strong quarter a year ago. Although reagent revenue remains a mid-single digit percentage of our total revenue, it climbed more than 20% in Q4 and more than 25% across all of 2025. As we've said before, this rapid expansion reflects several initiatives launched at the start of 2025, among them achieving industry-leading delivery times, providing a broad reagent catalog, establishing a new dedicated reagent sales team, and rolling out new reagent products. Our service business kept generating robust recurring revenue, expanding 25% during Q4 compared with the same quarter a year earlier. That performance stemmed from a bigger installed base along with heavier active use of our systems. We anticipate service will keep expanding for those same reasons, though the pace will ease step by step as more instruments get installed, which enlarges the denominator in that math. Now for how we did by region: overall U.S. revenue rose 5% in Q4 against the prior year, helped by service revenue climbing at a double-digit rate. EMEA posted 21% growth thanks to strong service and instrument revenue from academic and government customers. APAC, China included, was up 15% in Q4, powered by gains in instruments, service, and reagents. On a GAAP basis, gross profit came to $32.9 million, which is 2% lower than the $33.7 million recorded in Q4 of 2024. GAAP gross profit margin stood at 53%, compared with 59% a year earlier. Two things caused that: a weaker service gross margin stemming from more headcount and travel costs, plus a weaker product gross margin brought on by higher materials and tariff costs along with greater manufacturing overhead from duplicate costs tied to moving a production facility overseas. Adjusted gross profit margin, which leaves out stock-based compensation and amortization of acquisition-related intangibles, reached 55% in Q4, a drop from 61% in the same quarter last year. Total operating expenses in Q4 were $38.5 million, an increase of $7.8 million, or 25%, over Q4 of 2024, a quarter that contained a non-recurring expense reduction of $2.6 million tied to a change in estimate for a license and royalty settlement liability adjustment. Strip out that expense reduction and the rise was $5.2 million. Higher general and administrative plus sales and marketing expenses drove this, partly offset by reduced R&D. Research and development expenses totaled $9 million, 8% below the year ago quarter, mainly from lower headcount and compensation expenses as well as lower engineering expenses. Sales and marketing expenses reached $13.1 million, 11% above the year ago quarter, on account of higher headcount and compensation expenses and bigger sales commissions. General and administrative expenses came to $16.4 million, up $7.3 million from the year ago quarter, which contained the $2.6 million reduction I referenced earlier. Without that reduction, the increase would have been $4.7 million, or 40%. This rise was mostly driven by legal expenses connected to a patent litigation case plus higher compensation, software, and bad debt expenses. Loss from operations for Q4 was $5.6 million, against $3 million of income from operations in the year ago quarter, which had included the $2.6 million non-recurring expense reduction I mentioned earlier. Setting that amount aside, income from operations in Q4 2024 would have come to $0.3 million. The rest of the decline in income from operations, $5.9 million, reflected $0.8 million less gross profit and $5.2 million more in operating expenses. Net loss for Q4 was $44.1 million, versus net income of $9.6 million in the prior year quarter. For the quarter just reported, we posted a net loss of $44.1 million, and that figure reflects a valuation allowance of $38.1 million — essentially a write-off — recorded against deferred tax assets in accordance with ASC 740, driven by doubt about whether the related future tax benefits will actually be realized. That charge is purely an accounting conclusion; it has no bearing on our capacity to utilize these losses for tax purposes, and it involves no cash. On top of that, it's an exceptionally big number, since these deferred tax assets built up across several years, and never before had we recorded such a valuation allowance. If you set that valuation allowance aside, the net loss comes to $6.0 million. During Q4 2024, net income benefited from a non-recurring after-tax gain of $6.7 million tied to the settlement liability adjustment I referenced earlier. Strip that out, and net income would have been $2.9 million. The rest of the rise in net loss, amounting to $8.9 million, stemmed mainly from gross profit that was $0.8 million lower, operating expenses that were $5.2 million higher, and other tax expense that grew by $2.5 million, largely on foreign earnings. Adjusted EBITDA, which leaves out stock-based compensation along with the foreign exchange impact, fell to $4.5 million, down from $12.5 million in the same quarter last year, a period that contained the $2.6 million non-recurring benefit I described above. Take that amount out, and Adjusted EBITDA for Q4 2024 would have come to $9.9 million.
That $5.4 million drop came mostly from operating expenses running $5.2 million higher, along with gross profit that was $0.8 million lower. In Q4 2025, free cash flow was just barely negative — -$0.2 million — which nudged our total cash and marketable securities down slightly, to $261.5 million as of December 31, 2025, versus $261.7 million when the third quarter closed. Now let's move to Slide nine and look at the full year 2025. Revenue for the year that ended December 31, 2025, totaled $201.5 million, up 1% from the prior year. What drove that 2025 revenue increase was mainly 21% growth in service revenue worldwide plus double-digit growth in APAC product revenue, with a slowdown in EMEA and U.S. product revenue partly offsetting those gains. GAAP gross profit for 2025 came in at $104.5 million, which is 6% below the prior year's GAAP gross profit of $111.1 million. GAAP gross margin for 2025 was 52%, versus 55% a year earlier. The main reasons for that decline were more service headcount, higher material costs, higher tariffs, and greater manufacturing overhead costs stemming from moving the production facility overseas, as I mentioned earlier. Adjusted gross margin — which leaves out stock-based compensation and acquisition-related intangibles — was 55% for 2025, compared with 59% in the prior year. Operating expenses for 2025 reached $144.8 million, versus $131.6 million a year earlier, and that prior-year figure included the $2.6 million non-recurring reduction I described earlier. If you set aside that reduction along with a non-recurring ATM offering cost write-off in Q3 2025, the increase would have come to $9.9 million, or 7%. That was mostly the result of higher G&A costs, partly offset by lower R&D costs. Research and development expenses were $36.5 million, down from $39.4 million, a 7% decrease versus the year-ago quarter, largely because of reduced headcount and engineering expense. Sales and marketing expenses totaled $49.4 million, up 1% from $49.1 million in the year-ago quarter. General and administrative expenses came to $58.9 million, compared with $43.1 million in the year-ago quarter, which had included the $2.6 million reduction I mentioned earlier. Setting aside that reduction and the non-recurring offering cost write-off, the increase would have been $12.5 million, or 27%. That rise was mainly driven by higher legal expenses tied to the patent litigation case I mentioned earlier, along with higher compensation, sales and use tax, and software expenses. Our loss from operations in 2025 was $40.4 million, which included a $0.7 million non-recurring write-off of deferred ATM facility offering costs; that compares with a loss of $20.5 million in 2024, or $23.1 million once you exclude the $2.6 million non-recurring expense reduction I described earlier. Excluding both of those non-recurring items, loss from operations grew by $16.6 million, reflecting $6.6 million less gross profit and $9.9 million more in operating expenses. GAAP net loss for the year ended December 31, 2025, was $66.5 million. This figure takes into account a $33.1 million valuation allowance, essentially a write-off, recorded against deferred tax assets. As I explained earlier, this relates to Q4 and stems from uncertainty about whether those future tax benefits will actually be realized. Like I said before, the amount was unusually large because this was the first time we recorded such an allowance. Also included in the GAAP net loss was the $0.7 million non-recurring offering cost write-off I mentioned earlier. If you set those items aside, GAAP net loss for 2025 would have come to $32.7 million, versus a net loss of $6 million or $12.7 million once you exclude the $6.7 million non-recurring benefit from the settlement liability adjustment I described earlier. Setting aside these non-recurring items, GAAP net loss rose by $20 million in 2025. The reasons were $6.6 million lower gross profit, $9.9 million higher operating expenses, and $3.3 million higher taxes, largely tied to foreign earnings. Adjusted EBITDA came in at $5 million for 2025, which leaves out the non-recurring items I mentioned earlier, foreign exchange impacts, and stock-based compensation expense. That compares with $22.4 million in 2024. The $17.4 million decline was mainly attributable to $6.6 million lower gross profit, $9.9 million higher operating expenses, and $2.3 million lower stock-based compensation. Adjusted EBITDA, once investment income is excluded, fell from $14.4 million in 2024 to negative $3.1 million in 2025. True to our long-standing emphasis on controlling costs and staying profitable, we are dedicated to making these metrics better as we move forward. Cash, cash equivalents, and marketable securities came to $261.5 million as of December 31, 2025. That marks a $16.4 million drop from the $277.9 million recorded at the close of December 2024, partly driven by our repurchase of $15.1 million of Cytek stock under our stock repurchase program during 2025. Through that $15.1 million, we bought back roughly 3.3 million shares at a weighted average cost of $4.58 per share, which left us with 128.6 million shares outstanding as of December 31, 2025. A strong balance sheet and positive cash generation highlight our capacity to put money into our global growth initiatives. Moving to our full year guidance on Slide 10, we are starting our 2026 revenue outlook at $205 million-$212 million, with constant currency exchange rates assumed. At this point, we are also not factoring in any meaningful benefit from shifts in the tariff landscape as we look ahead. This guidance range captures the better market conditions in EMEA and the U.S., along with continued strong growth in APAC instruments and in our service and reagent businesses worldwide. We anticipate these trends will persist. Crucially, we still hold the view that our results in Q4 and full year 2025 demonstrate a strong market leadership position amid what has been a tough environment. Positive growth is now appearing across all major regions in our core business, and our recurring revenue keeps expanding. Even with some temporarily elevated operating expenses, we achieved positive Adjusted EBITDA for full year 2025, and we expect that to carry on in 2026. As we have in the past, we believe we will keep outperforming the broader flow cytometry market, which is likewise starting to display signs of stabilization. Having said that, I'll now hand things back to Wenbin.
Appreciate it, Bill. Moving over to Slide 11. To wrap things up, I'd like to express gratitude to the entire Cytek team; during this year, TIME Magazine named us a growth leader among public companies in America; that recognition speaks to the remarkable growth and innovation track record Cytek has built across the past 5 years. On the whole, I think the results we posted in Q4 and for the full year amid a difficult 2025 demonstrate how resilient our organization is and how strong our leadership position is within the flow cytometry market. The breadth of our execution sets us up well going into 2026, when our focus will stay on expanding market penetration for our instrument platforms, pressing ahead with technological leadership through innovative new products, fueling expansion in our recurring revenue lines, and achieving profitable, sustainable growth. Thank you all for being part of today's call, and at this point we'll take questions. Operator?
Thanks — I appreciate you taking my questions, and all the detail you provided. I wanted to step back and ask something at a slightly higher level, about a few of the assumptions sitting underneath growth in the flow cytometry market as a whole. You gave us a lot of useful detail on the various end markets. My understanding is that we're looking at something around an 8%-9% CAGR, possibly through 2031 or 2032, unless I've got that wrong. Setting aside whatever the precise figure is, given your worldwide footprint, can you give me a sense of how that growth breaks down across the different end markets? To phrase that differently, I'm curious whether there are geographic factors related to growing the market where you'd be, or might be, in a stronger spot to take advantage, particularly because of how strong you are in APAC? I'm just sort of asking how you look at that in general. Thanks, everyone.
Yes, I believe. Hey, Brendan, Bill here. I believe, well, we've observed steady growth at a double-digit rate in the APAC market, or at least in what we earn in APAC. Perhaps we performed somewhat above the market, especially, well, because of our expansion in sorters and the Aurora franchise. Our general impression is that this particular region's market is expanding at a solid rate somewhere in the middle single-digit range, maybe even toward the upper portion of that band. As we see it, Europe is likely the weakest-performing market — at least that's been true for our business — while the U.S. sits somewhere between those two. Based on what we recorded, our belief is that we outperformed the overall market in the U.S. as well as in EMEA. Pinpointing exactly how those regional markets are performing is genuinely difficult. Some of our competitors have posted negative growth, we've noticed, though drawing firm conclusions from that isn't easy. Wenbin, anything else you'd like to add?
No, I believe that captures it nicely.
See, I'd say, well, over the past 2 years, the rates at which the market has expanded have definitely come in under what most forecasts—most of those market studies projecting 5-year growth for flow cytometry—have suggested; those forecasts point to rates in the high single digits worldwide, and clearly, for the last 2 years, we've been under that level for the time being. We do anticipate a rebound, you know.
Understood! That tracks. Appreciate it, everyone.
Hello, I'm Skye, filling in for David. Thanks for letting me ask. To kick things off, how much did growth speed up by the end of the year, and what caused that? Was it mostly down to academic budget cycles, or is pharma spending bouncing back? And how should we frame budgets for 2026? Thanks.
As I noted in my remarks, what we observed was an environment getting better in every quarter of 2025. Q1 wasn't great, with revenue growth at -8%; then things steadied to -2% in Q2, +2% in Q3, and +8% in Q4. My sense is that this came from a normalization — both a normalization in the academic and government spending market. We saw certain catch-up disbursements from the NIH, plus, we believe, some catch-up spending that had been pushed off from earlier in the year. Every one of those elements was in play. We also got a currency tailwind in EMEA. Putting it all together, the uncertainties that weighed on the markets during the early part of 2025, especially Q1, appear to have faded, and things are improving. Academic and government had a particularly strong quarter in Q4. As I said, we believe there's a mix of genuinely better sentiment plus some catch-up, and in our guidance we're assuming that more positive environment continues.
Right.
Thanks.
When looking at the fourth quarter, both the academic side and the government side performed strongly on a worldwide basis.
For the entire year, academic and government grew 5%, and during the second half it was 9%, and this applies to both our product and service businesses. That growth in academic and government in the second half is, you know, obviously quite solid.
That's quite useful, thanks. One final question: how did things split during 2025 when it came to bringing on brand-new buyers as opposed to current ones who perhaps scaled up their capacity? Any sense of what that split might look like in 2026? Thanks.
Right, we don't actually provide those figures separately. I'd just say both categories play a part. You know, plenty of our buyers have acquired several systems and keep favoring our technology. As we've mentioned before, once pharma companies settle on a technology, they usually remain loyal to it. We're additionally witnessing switches away from rival systems.
Hello there, good afternoon, and thank you for taking my questions. This is Ben, sitting in for Mason. What's your current thinking regarding your commercial investments in 2026? Do you feel at ease with how large the sales teams are right now? Are there any areas where you plan to put money to work over the coming year?
Yes. Broadly speaking, as you're able to see, our emphasis has been on the high end of the market segment, exemplified by offerings such as Aurora Evo and Aurora Cell Sorter, and those posted double-digit growth both last year and in Q4. Turning now to the commercial side, it's obvious we're reviewing the segment, we are plainly weak there, and we will keep putting investment into those segments so as to fuel revenue growth going forward.
Yes, we've put money into our reagent sales team too. Investment will keep being directed toward the commercial side as a key priority.
Understood, thanks. How open would you be to adjusting prices during this year so that instrument placements get a boost?
For Cytek, what we charge has always been shaped by the market, our cost structure remains highly competitive, and we are able to handle whatever circumstances arise, whenever necessary.
Understood. Appreciate you fielding our questions.
Hi, everyone, and thanks for making room for us. Perhaps only a single item — there were a remark or two earlier regarding pent-up demand giving a lift to 4Q. Could you help us gauge how large a piece of that came from volume that was essentially made up from sooner in the year or from prior years, against what you'd call the business's steady state growth trajectory, given where things stand now in the current end market?
Yes, that one's tough to pin down. I'd say, if you take our academic and government revenues in total, which we do disclose publicly, beginning with last year's fourth quarter, the figures ran $21 million, then $17 million, $22 million, $18 million, and $28 million in Q4. There was a notable step up in that period. Like I mentioned, much of it comes down to a stronger environment. It's equally plausible that a portion of those softer figures early in 2025 amounted to nothing more than money being deferred and then spent afterward in the year; pausing it out is genuinely possible. To really know, you'd need to survey each customer individually and dig into what they intended, and clearly, that isn't something we do.
All right, perhaps just considering that.
In my view, the pharma segment is considerably more steady, and, as you're aware, in that area our revenue held quite consistent from Q3 to Q4 — it was essentially unchanged.
Absolutely, that's useful. So perhaps if I just consider the guidance for a moment and try to frame it alongside a few of those remarks. You've just posted roughly 5% organic. You mention the market seems to be improving somewhat, becoming a bit more steady, and your outlook for the year is 2%-5% growth. What has to occur in the end market for you to view 2% as the correct figure rather than 5%? And what has to occur to push you above that, given we're already assuming conditions may be somewhat stronger across most of 2026 than they were across most of 2025?
Yes. Our approach to the guidance was this: we anticipate continued robust expansion in service and reagents. On the service side, that's because our installed base keeps getting larger, and on reagents, well, we're beginning from a small base and expanding rapidly. For instruments, we anticipated growth that was flat to modest. After that, honestly, we built in a set of contingencies to cover uncertainties, since at this same point 1 year ago, certain black swans had appeared. We wanted a cushion in place for those kinds of situations. That's what shaped our thinking behind the range. At the upper end of the range, clearly, that would mean a reduced amount of contingency, along with, well, stronger results in the instrument business.
Okay, I'll stop there. Thank you.
Since nobody else has anything to ask, that brings today's conference call to a close. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytek Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Cytek Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.